Analyst: Wegovy prescriptions in US signal strong start to 2023
A Sydbank analyst reacts positively to recent prescription figures for Novo Nordisk’s newest obesity drug, Wegovy, in the first two weeks of 2023.
by marketwire, translated by daniel pedersen
Novo Nordisk’s obesity treatment, Wegovy, is off to a great start in 2023, says Senior Equity Analyst Søren Løntoft Hansen at Danish bank Sydbank, looking at the latest prescription figures from Symphony Health Solutions.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Norway denies Novo Nordisk reimbursement for obesity drug
For subscribers
